- Home
- AAPG vs LNTH Comparison
AAPG vs LNTH Comparison
Compare AAPG & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAPG
- LNTH
- Stock Information
- Founded
- AAPG 2009
- LNTH 1956
- Country
- AAPG China
- LNTH United States
- Employees
- AAPG N/A
- LNTH N/A
- Industry
- AAPG Biotechnology: Pharmaceutical Preparations
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- AAPG Health Care
- LNTH Health Care
- Exchange
- AAPG Nasdaq
- LNTH Nasdaq
- Market Cap
- AAPG 3.6B
- LNTH 3.8B
- IPO Year
- AAPG 2025
- LNTH 2015
- Fundamental
- Price
- AAPG $32.00
- LNTH $55.20
- Analyst Decision
- AAPG Strong Buy
- LNTH Buy
- Analyst Count
- AAPG 3
- LNTH 6
- Target Price
- AAPG $49.00
- LNTH $74.17
- AVG Volume (30 Days)
- AAPG 7.7K
- LNTH 1.3M
- Earning Date
- AAPG 11-19-2025
- LNTH 11-06-2025
- Dividend Yield
- AAPG N/A
- LNTH N/A
- EPS Growth
- AAPG N/A
- LNTH N/A
- EPS
- AAPG N/A
- LNTH 2.39
- Revenue
- AAPG $54,524,554.00
- LNTH $1,525,933,000.00
- Revenue This Year
- AAPG N/A
- LNTH N/A
- Revenue Next Year
- AAPG $368.64
- LNTH $1.98
- P/E Ratio
- AAPG N/A
- LNTH $22.78
- Revenue Growth
- AAPG N/A
- LNTH 1.95
- 52 Week Low
- AAPG $16.50
- LNTH $47.25
- 52 Week High
- AAPG $48.45
- LNTH $111.29
- Technical
- Relative Strength Index (RSI)
- AAPG 41.98
- LNTH 49.67
- Support Level
- AAPG $30.93
- LNTH $50.16
- Resistance Level
- AAPG $34.31
- LNTH $61.92
- Average True Range (ATR)
- AAPG 0.81
- LNTH 2.65
- MACD
- AAPG 0.06
- LNTH -0.43
- Stochastic Oscillator
- AAPG 48.79
- LNTH 40.59
About AAPG Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.